
Oncocyte Corp (IMDX) Stock Forecast & Price Target
Oncocyte Corp (IMDX) Analyst Ratings
Bulls say
Insight Molecular Diagnostics Inc. is positioned for substantial long-term revenue growth driven by its innovative diagnostic tests for organ transplant monitoring and cancer. The company's ongoing rebranding of its GraftAssure product line and the expansion of its addressable market, which could see a 10-20% increase through additional reimbursement for new testing indications, further support this optimistic projection. Key catalysts for growth include favorable clinical data, potential guideline changes from the National Comprehensive Cancer Network (NCCN), and accelerated revenue generation, all of which reinforce the company's strong market potential.
Bears say
Insight Molecular Diagnostics Inc. has experienced a significant decline in gross margin, decreasing from 67.6% in 2Q25 to 53.5%, despite surpassing estimates. Additionally, while operating expenses were slightly higher than anticipated, the company's cash burn remains a concern, with risks including slower physician adoption, reimbursement uncertainties, and potential dilution from equity offerings. Furthermore, the company may face limited revenue generation from its GraftAssureIQ assay until the anticipated IVD clearance for GraftAssureDx, projected for mid-2026.
This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.
Oncocyte Corp (IMDX) Analyst Forecast & Price Prediction
Start investing in Oncocyte Corp (IMDX)
Order type
Buy in
Order amount
Est. shares
0 shares